{
    "clinical_study": {
        "@rank": "149574", 
        "arm_group": {
            "arm_group_label": "Pregnant women", 
            "description": "Pregnant women of 13-22 weeks gestation"
        }, 
        "brief_summary": {
            "textblock": "The primary goal of this study is to examine the efficacy and feasibility of a mifepristone\n      combined with misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in\n      Armenia."
        }, 
        "brief_title": "Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia", 
        "condition": [
            "Women, Pregnant", 
            "13-22 Weeks Gestation"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria, aside from being in good general health and have a pregnancy of 13-22\n        weeks gestation:\n\n          1. Meet legal criteria to obtain abortion\n\n          2. Present with closed cervical os and no vaginal bleeding\n\n          3. Live fetus at time of presentation for service\n\n          4. Be willing to undergo a surgical completion if necessary\n\n          5. Have no contraindications to study procedures, according to provider\n\n          6. Be willing and able to consent to procedure, either by reading consent document or by\n             having consent document read to her\n\n          7. Be willing to follow study procedures\n\n        Exclusion criteria:\n\n          1. Known previous transmural uterine incision\n\n          2. Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications\n             to the use of mifepristone or misoprostol\n\n          3. Parity greater than 5.\n\n          4. Any contraindications to vaginal delivery, including placenta previa\n\n          5. Presentation in active labor (defined as moderate to severe contractions every 10\n             minutes or less)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All women presenting to a study clinic in Yerevan, Armenia for voluntary termination of\n        intrauterine pregnancy with gestational ages of 13-22 weeks"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766388", 
            "org_study_id": "1005"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mifepristone", 
                "Misoprostol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 9, 2013", 
        "location": [
            {
                "contact": {
                    "email": "r_abrahamyan@mail.ru", 
                    "last_name": "Ruzanna Abrhamyan, MD", 
                    "phone": "(+374 91) 40 57 18"
                }, 
                "facility": {
                    "address": {
                        "city": "Yerevan", 
                        "country": "Armenia", 
                        "zip": "0078"
                    }, 
                    "name": "Republican Institute of Reproductive Health, Perinatology, Obstetrics and Gynecology"
                }, 
                "investigator": {
                    "last_name": "Ruzanna Abrahamyan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gavagyan@moh.am", 
                    "last_name": "Gayane Avagyan, MD, PhD", 
                    "phone": "(+374 91) 45 81 35"
                }, 
                "facility": {
                    "address": {
                        "city": "Yerevan", 
                        "country": "Armenia", 
                        "zip": "0025"
                    }, 
                    "name": "State Medical University"
                }, 
                "investigator": {
                    "last_name": "Gayane Avagyan, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Armenia"
        }, 
        "number_of_groups": "1", 
        "official_title": "Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Armenia", 
        "overall_official": [
            {
                "affiliation": "Republican Institute of Reproductive Health, Perinatology, Obstetrics and Gynecology", 
                "last_name": "Ruzanna Abrahamyan, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "State Medical University", 
                "last_name": "Gayane Abrahamyan, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gynuity Health Projects", 
                "last_name": "Beverly Winikoff, MD, MPH", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Armenia: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Rate of successful abortion", 
                "safety_issue": "No", 
                "time_frame": "Every 3 hours after induction with misoprostol commences, up to 30 hours after the first dose"
            }, 
            {
                "measure": "Induction to fetal expulsion interval", 
                "safety_issue": "No", 
                "time_frame": "Time from administration of first misoprostol dose to expulsion of the fetus, up to 30 hours after the first dose"
            }, 
            {
                "measure": "Induction to fetal and placental expulsion interval", 
                "safety_issue": "No", 
                "time_frame": "Time from administration of first misoprostol dose to expulsion of the fetus and placenta, up to 30 hours after the first dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766388"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total dose of misoprostol", 
                "safety_issue": "No", 
                "time_frame": "At the time of fetal and placental expulsion, up to 30 hours after the first dose"
            }, 
            {
                "measure": "Women's satisfaction with the method", 
                "safety_issue": "No", 
                "time_frame": "At discharge, up to 5 days after enrollment"
            }, 
            {
                "measure": "Side effects", 
                "safety_issue": "No", 
                "time_frame": "Every 3 hours, starting from the first dose of misoprostol, up to fetal and placental expulsion or 30 hours after the first dose, whichever occurs first"
            }, 
            {
                "measure": "Women's acceptability of the side effects, buccal administration of misoprostol, and duration of procedure", 
                "safety_issue": "No", 
                "time_frame": "At discharge, up to 5 days after enrollment"
            }, 
            {
                "measure": "Providers' acceptability of the method", 
                "safety_issue": "No", 
                "time_frame": "After all study procedures complete, at close out, up to 1.5 years after study enrollment commences"
            }, 
            {
                "measure": "Complications including heavy bleeding, uterine rupture, or infection requiring additional treatment", 
                "safety_issue": "No", 
                "time_frame": "Every 3 hours, starting from the first dose of misoprostol, up to fetal and placental expulsion, or 30 hours after the first dose, whichever occurs first"
            }
        ], 
        "source": "Gynuity Health Projects", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gynuity Health Projects", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}